Prevention of Delirium in Intensive Care by Melatonin
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, Phase 2b/3 two-part adaptive clinical
trial. The trial is designed to investigate the pharmacokinetics and the efficacy of multiple
dosing regimens of melatonin and to confirm the efficacy and safety of one dosing regimen in
prevention for delirium.